Edition:
United States

Zimmer Biomet Holdings Inc (ZBH.N)

ZBH.N on New York Stock Exchange

110.32USD
4:01pm EDT
Change (% chg)

$-0.42 (-0.38%)
Prev Close
$110.74
Open
$111.06
Day's High
$112.17
Day's Low
$109.86
Volume
491,514
Avg. Vol
309,549
52-wk High
$133.45
52-wk Low
$104.28

Summary

Name Age Since Current Position

Larry Glasscock

69 2013 Independent Non-Executive Chairman of the Board

Bryan Hanson

50 2017 President, Chief Executive Officer, Director

Daniel Florin

53 2017 Chief Financial Officer, Senior Vice President

Robert Delps

2017 President, Americas

Katarzyna Mazur-Hofsaess

52 2013 President, Europe, Middle East and Africa

Sang Yi

54 2015 President, Asia Pacific

Chad Phipps

44 2007 Senior Vice President, General Counsel, Secretary

Coleman Lannum

51 2018 Senior Vice President - Investor Relations

Christopher Begley

65 2012 Independent Director

Betsy Bernard

61 2009 Independent Director

Gail Boudreaux

56 2012 Independent Director

Michael Farrell

45 2014 Independent Director

Robert Hagemann

60 2008 Independent Director

Arthur Higgins

61 2007 Independent Director

Michael Michelson

65 2015 Independent Director

Cecil Pickett

71 2008 Independent Director

Jeffrey Rhodes

42 2015 Independent Director

Matt Abernethy

38 2017 CPA, Vice President, Investor Relations

Biographies

Name Description

Larry Glasscock

Mr. Larry C. Glasscock is Independent Non-Executive Chairman of the Board of the Company. He served as the Chairman of WellPoint, Inc. (now Anthem, Inc.) from 2005 until 2010. Mr. Glasscock also served as President and Chief Executive Officer of WellPoint, Inc. from 2004 to 2007. Mr. Glasscock served as Chairman, President and Chief Executive Officer of Anthem, Inc. from 2003 to 2004 and served as President and Chief Executive Officer of Anthem, Inc. from 2001 to 2003. Mr. Glasscock earned a B.B.A. from Cleveland State University. He also completed the Commercial Bank Management Program at Columbia University.

Bryan Hanson

Mr. Bryan C. Hanson is President, Chief Executive Officer, Director of the Company. Mr. Hanson joins Zimmer Biomet with more than 20 years of experience in the medical device industry. Most recently, he served as a member of Medtronic's Executive Committee and as the Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group, where he oversaw and provided strategic direction to this approximately $9 billion business. Prior to Medtronic, Mr. Hanson served in a number of executive roles of increasing responsibility. In 2013, he was named Group President of Covidien's Medical Devices business. In 2011, as Surgical Solutions Group President, Mr. Hanson transformed two of Covidien's largest divisions-Energy-based Devices and Surgical Devices-into one global business unit. Mr. Hanson also serves on the board of AmeriCares, an emergency response and global health organization committed to saving lives and building healthier futures for people in crisis.

Daniel Florin

Mr. Daniel P. Florin is Chief Financial Officer, Senior Vice President of the Company. He was appointed Senior Vice President and Chief Financial Officer of Zimmer Biomet in June 2015 and has over 16 years of executive experience in the medical device industry. He previously served as Senior Vice President and Chief Financial Officer of Biomet from June 2007 to June 2015. Prior to joining Biomet, Mr. Florin served as Vice President and Corporate Controller of Boston Scientific Corporation from 2001 until 2007. Before being appointed Corporate Controller in 2001, Mr. Florin served in financial leadership positions within Boston Scientific Corporation and its various business units. Mr. Florin previously worked for C.R. Bard from October 1990 through June 1995, and Deloitte from September 1986 to October 1990. Mr. Florin holds a Bachelor’s degree in Business Administration with a concentration in Accounting from the University of Notre Dame and an Executive MBA from Boston University.

Robert Delps

Mr. Robert D. Delps is President, Americas of the Company. Mr. Delp brings 20 years of sales leadership experience to his new role, including eight years as Biomet Vice President of Sales for several businesses, including Sports Medicine, Extremities, Trauma and Biologics, prior to the combination of Zimmer and Biomet.

Katarzyna Mazur-Hofsaess

Dr. Katarzyna Mazur-Hofsaess, M.D., Ph.D. is no longer President, Europe, Middle East and Africa of the Company effective May 31, 2018. Dr. Mazur-Hofsaess joined the Company (then Zimmer) in February 2010 as Senior Vice President, EMEA Reconstructive. She has more than 20 years’ experience within the pharmaceutical, diagnostics and medical device sectors. Prior to joining Zimmer, Dr. Mazur-Hofsaess served in various management positions at Abbott Laboratories beginning in 2001, most recently as Vice President, Diagnostics – Europe.

Sang Yi

Mr. Sang Yi is President, Asia Pacific of the Company. He is responsible for the sales, marketing and distribution of products in the Asia Pacific region. Mr. Yi joined the Company (then Zimmer) in March 2013 as Senior Vice President, Asia Pacific. Before joining Zimmer, he served as Vice President and General Manager of St. Jude Medical for Asia Pacific and Australia from 2005 to 2013. Prior to that, Mr. Yi held several leadership positions over a ten-year period with Boston Scientific Corporation, ultimately serving as Vice President for North Asia.

Chad Phipps

Mr. Chad F. Phipps is Senior Vice President, General Counsel, Secretary of the Company. He has global responsibility for the Company’s Legal Affairs and he serves as Secretary to the Board of Directors. Mr. Phipps also oversees the Company’s Government Affairs, Corporate Communication and Public Relations activities. Previously, Mr. Phipps served as Associate General Counsel and Corporate Secretary from December 2005 to May 2007. He joined the Company (then Zimmer) in September 2003 as Associate Counsel and Assistant Secretary. Prior to joining Zimmer, he served as Vice President and General Counsel of L&N Sales and Marketing, Inc. in Pennsylvania and he practiced law with the firm of Morgan, Lewis & Bockius in Philadelphia, focusing on corporate and securities law, mergers and acquisitions and financial transactions.

Coleman Lannum

Mr. Coleman N. Lannum is Senior Vice President - Investor Relations of the Company. Mr. Lannum joins Zimmer Biomet with more than 15 years of Investor Relations (IR) experience in the healthcare industry. Most recently, he served as Senior Vice President of Investor Strategy and Investor Relations Officer for Mallinckrodt Pharmaceuticals, where he consulted with executive management and the Board of Directors regarding the Company's acquisitions, strategic direction and shareholder value optimization. Prior to joiningMallinckrodtin 2015, Mr. Lannum led IR at Covidien and Tyco Healthcare for nine years. As Vice President and Investor Relations Officer, he designed Covidien's IR program, oversaw the largest-ever healthcare Initial Public Offering and led the IR effort through the company's merger with Medtronic in 2015. Mr. Lannum's leadership at Covidien andMallinckrodthas been recognized with numerous best-in-class honors, including an unprecedented five consecutive awards by IR Magazine for both Best US Investor Relations Officer - Large Cap and Grand Prix - Best Overall Investor Relations from 2011 through 2015.

Christopher Begley

Mr. Christopher B. Begley is Independent Director of the Company. He served as Executive Chairman of the Board of Hospira, Inc. from May 2007 until his retirement in January 2012. Mr. Begley also served as Chief Executive Officer from April 30, 2004, when Hospira was spun off from Abbott Laboratories, to March 2011. Prior to that, Mr. Begley served in various positions with Abbott between 1986 and 2004, most recently as Senior Vice President of Abbott’s Hospital Products division. He earned a bachelor’s degree from Western Illinois University and an MBA from Northern Illinois University.

Betsy Bernard

Ms. Betsy J. Bernard is Independent Director of the Company. Ms. Bernard is the President of AT&T Corp. from October 2002 until her retirement in December 2003. From April 2001 to October 2002, Ms. Bernard was Chief Executive Officer of AT&T Consumer. Prior to joining AT&T, Ms. Bernard held senior executive positions with Qwest Communications International Inc., US WEST, Inc., AVIRNEX Communications Group and Pacific Bell. Ms. Bernard received a B.A. degree from St. Lawrence University, an MBA from Fairleigh Dickenson University and an M.S. in management from Stanford University’s Sloan Fellowship Program.

Gail Boudreaux

Ms. Gail Koziara Boudreaux is Independent Director of the Company. Ms. Boudreaux was the Chief Executive Officer and Founder, GKB Global Health, LLC from 2015 to present. Ms. Boudreaux served as Chief Executive Officer of UnitedHealthcare from January 2011 to November 2014 and Executive Vice President of UnitedHealth Group from May 2008 to February 2015. From 2005 to 2008, Ms. Boudreaux served as Executive Vice President, External Operations for Health Care Services Corporation (“HCSC”), and prior to that served as President of Blue Cross and Blue Shield of Illinois, a division of HCSC. Before joining HCSC, Ms. Boudreaux held various positions at Aetna, including Senior Vice President, Aetna Group Insurance. Ms. Boudreaux earned a bachelor’s degree in psychology from Dartmouth College and an MBA from Columbia Business School.

Michael Farrell

Mr. Michael J. Farrell is Independent Director of Zimmer Biomet Holdings, Inc. He served as Chief Executive Officer of ResMed Inc. since March 2013. Prior to that appointment, Mr. Farrell served as President – Americas for ResMed from 2011 to 2013. He was previously Senior Vice President of the global business unit for sleep apnea therapeutic and diagnostic devices from 2007 to 2011, and before that he held various senior roles in marketing and business development. Before joining ResMed in September 2000, Mr. Farrell worked in management consulting, biotechnology, chemicals and metals manufacturing at Arthur D. Little, Genzyme Corporation, The Dow Chemical Company and BHP Billiton. Mr. Farrell holds a bachelor of engineering, with first-class honors, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology and an MBA from the MIT Sloan School of Management.

Robert Hagemann

Mr. Robert A. Hagemann is Independent Director of Zimmer Biomet Holdings, Inc. He served as the Senior Vice President and Chief Financial Officer of Quest Diagnostics Incorporated until his retirement in July 2013. Mr. Hagemann joined Corning Life Sciences, Inc., a subsidiary of Quest Diagnostics’ former parent company, Corning Incorporated, in 1992, and held roles of increasing responsibility before being appointed Chief Financial Officer of Quest Diagnostics in 1998. Prior to joining Corning, Mr. Hagemann held senior financial positions at Prime Hospitality, Inc. and Crompton & Knowles, Inc. He was also previously employed by Arthur Young & Co., a predecessor company to Ernst & Young. Mr. Hagemann holds a B.S. in accounting from Rider University and an MBA from Seton Hall University.

Arthur Higgins

Mr. Arthur J. Higgins is Independent Director of Zimmer Biomet Holdings, Inc. He is Consultant, Blackstone Healthcare Partners of The Blackstone Group, since June 2010. Prior to that, Mr. Higgins served as Chairman of the Board of Management of Bayer HealthCare AG from January 2006 to May 2010 and Chairman of the Bayer HealthCare Executive Committee from July 2004 to May 2010. Prior to joining Bayer HealthCare in 2004, Mr. Higgins served as Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, Inc. from 2001 to 2004. Prior to that, Mr. Higgins spent 14 years with Abbott Laboratories, most recently as President of the Pharmaceutical Products Division from 1998 to 2001. He graduated from Strathclyde University, Scotland and holds a B.S. in biochemistry.

Michael Michelson

Mr. Michael W. Michelson is Independent Directorof the Company. Mr. Michelson served as Member, KKR Management LLC, a private equity investment manager and the general partner of KKR & Co. L.P., since October 2009. Before that, Mr. Michelson was a member of the limited liability company that served as the general partner of Kohlberg Kravis Roberts & Co. L.P. since 1996. He joined KKR in 1981. Mr. Michelson has played a significant role in the development of KKR’s portfolio companies. He began his professional career with the law firm of Latham & Watkins in Los Angeles, where he was involved in a broad corporate practice while specializing in management buyouts. He earned an A.B. from Harvard College and a J.D. from Harvard Law School.

Cecil Pickett

Dr. Cecil B. Pickett, Ph.D., is Independent Director of Zimmer Biomet Holdings, Inc. He is the President, Research and Development and a member of the board of directors of Biogen Idec Inc. from September 2006 until his retirement in October 2009. Prior to joining Biogen Idec, Dr. Pickett held several senior R&D positions, including Corporate Senior Vice President of Schering-Plough Corp. and President of Schering-Plough Research Institute. Prior to joining Schering-Plough, he held several senior R&D positions at Merck & Co. Dr. Pickett received a B.S. in biology from California State University at Hayward and a Ph.D. in cell biology from University of California at Los Angeles.

Jeffrey Rhodes

Mr. Jeffrey K. Rhodes is Director of the Company. Mr. Rhodes is Partner, TPG Capital, L.P. Mr. Rhodes is a leader of the firm’s investment activities in the healthcare services, pharmaceutical and medical device sectors. Prior to joining TPG in 2005, Mr. Rhodes was with McKinsey & Company and Article27 LTD, a start-up software company. He was a founding board member of the Healthcare Private Equity Association, a non-profit trade association that represents the U.S. healthcare private equity industry. Mr. Rhodes earned a B.A. in Economics from Williams College, where he graduated summa cum laude, and an MBA from Harvard Business School, where he was a Baker Scholar.

Matt Abernethy

Basic Compensation